ClinicalTrials.gg
CompletedNCT01560403STEPS3Updated Jun 10, 2021Results posted

A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021

A Phase 3 interventional study of Teduglutide in Short Bowel Syndrome, sponsored by Shire. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-10.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.

Enrollment
11th of 20
14 · median 20
Started
2012
the only one that year
Phase 3
16 of 20
none open now
Registered
6th of 20
by date
Lead sponsor
13 of 20
Shire

Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 11th largest by enrollment, is the only one that started in 2012, is one of 16 in phase 3, and was the 6th registered.

Short Bowel Syndrome

159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.

Browse Short Bowel Syndrome studies →

Open to participants now

1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About teduglutide

teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing teduglutide in Short Bowel Syndrome, or all of them as a file.
02

Study summary

This study is a 1-year open label extension study to collect long term efficacy and safety data from patients who have completed approximately 2 years of dosing in Study CL0600-021.

Read the detailed description

This study served as a 1-year extension study for those US patients who have completed the CL0600-021 study.

03

Conditions studied

  • Short Bowel Syndrome

Browse trials for

Keywords

  • Parenteral nutrition
  • TPN
  • HPN
  • PN
  • SBS
  • Short bowel syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At completion of Study CL0600-021, subjects will be invited to participate in this trial if they meet the following criteria:

    1. Completion of the 24-month study, CL0600-021, regardless if fully weaned from PN/I.V. support
    2. Signed and dated form (ICF) to participate before any study-related procedures of Study TED-C11-001 are performed

Exclusion criteria

Exclusion Criteria:

  • None
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Teduglutide

    0.05 mg/kg/day

    Drug: Teduglutide

Interventions

  • 0.05 mg/kg/day subcutaneously taken once per day for 12 months

    Also known as: Gattex

06

What researchers measure

Primary outcomes

  1. Summary of Treatment-emergent Adverse Events

    As the primary intent of this study was to collect additional safety data, this outcomes measure will provide a summary of the treatment emergent adverse events. Based on the start date of each subject in this study and the study end date, not all subjects reached 12 months.

    Time frame: 12 months

07

Results

Posted Dec 25, 2014
Limitations and caveats
This study provided further long-term safety and efficacy data on the 14 US subjects who enrolled in the CL0600-020 and the CL0600-021 study. Given the small number of subjects in this study, only descriptive statistics were employed and presented.

Participant flow

This was a 1-year, open-label, multi-center study in subjects who completed Study CL0600-021 (NCT00930644) at any US site.

Participant flow — Overall Study
MilestoneTED/TEDNT/PBO,TED
Started59
Completed58
Not completed01
Withdrew: Lost to follow-up01

Outcome measures

PrimarySummary of Treatment-emergent Adverse Events

As the primary intent of this study was to collect additional safety data, this outcomes measure will provide a summary of the treatment emergent adverse events. Based on the start date of each subject in this study and the study end date, not all subjects reached 12 months.

Time frame:
12 months
Reported as:
Number · participants
Summary of Treatment-emergent Adverse Events
participantsNT,PBO/TEDTED/TED
Summary of Treatment-emergent Adverse Events45

Adverse events

Collected over 1 year, 2 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NT/PBO,TED—1/9 (11.1%)4/9 (44.4%)
TED/TED—5/5 (100%)4/5 (80%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventNT/PBO,TEDTED/TED
Atrial fibrillationCardiac disorders0/91/5
Atrial tachycardiaCardiac disorders0/91/5
Cardiac failure acuteCardiac disorders0/91/5
Cardiac failure congestiveCardiac disorders0/91/5
CardiomyopathyCardiac disorders0/91/5
Ischaemic cardiomyopathyCardiac disorders0/91/5
Central line infectionInfections and infestations0/91/5
PneumoniaInfections and infestations0/91/5
Urinary tract infectionInfections and infestations0/91/5
In-stent arterial restenosisInjury, poisoning and procedural complications0/91/5
Most frequent other events
Showing 10 of 19
Most frequent other events
EventNT/PBO,TEDTED/TED
DiarrhoeaGastrointestinal disorders1/92/5
Catheter sepsisInfections and infestations0/92/5
DyspnoeaRespiratory, thoracic and mediastinal disorders0/92/5
Weight decreasedInvestigations0/92/5
Asthenic conditionsGeneral disorders2/91/5
Abdominal painGastrointestinal disorders2/90/5
Benign neoplasms gastrointestinalNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/90/5
Cognition and attention disorders and disturbancesPsychiatric disorders2/90/5
HypersensitivityImmune system disorders2/90/5
Viral infectionInfections and infestations2/90/5

Baseline characteristics

Age, Customized
Age, Customized(Participants)TED/TEDNT/PBO,TEDTotal
< 45 years123
45 - < 65 years369
>=65 years112
Sex: Female, Male
Sex: Female, Male(Participants)TED/TEDNT/PBO,TEDTotal
Female4610
Male134
08

Study locations

5 sites
  • Scripps Clinic & Research Foundation
    La Jolla, California 92037, United States
  • Emory University School of Medicine
    Atlanta, Georgia 30322, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
09

References and documents

Publications

  • Seidner DL, Fujioka K, Boullata JI, Iyer K, Lee HM, Ziegler TR. Reduction of Parenteral Nutrition and Hydration Support and Safety With Long-Term Teduglutide Treatment in Patients With Short Bowel Syndrome-Associated Intestinal Failure: STEPS-3 Study. Nutr Clin Pract. 2018 Aug;33(4):520-527. doi: 10.1002/ncp.10092. Epub 2018 May 15. PubMed 29761915 ↗

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2012 to primary completion in Jul 2013, 14 months.

Results were first posted in Dec 2014, 1 year 5 months after primary completion.

Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 14 months is below that.

Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2012
First posted
Mar 22, 2012
StartActual
May 21, 2012
Primary completionActual
Jul 23, 2013
CompletionActual
Jul 23, 2013
Results first posted
Dec 25, 2014
Last update
Jun 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01560403
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Mar 22, 2012
Start date
May 21, 2012
Primary completion
Jul 23, 2013
Completion
Jul 23, 2013
Results posted
Dec 25, 2014
Last update
Jun 10, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teduglutide

Start the discussion